Selection of DNA nanoparticles with preferential binding to aggregated protein target

Laura E. Ruff, Ajay A. Sapre, Justin S. Plaut, Elisabeth De Maere, Charlotte Mortier, Valerie Nguyen, Kevin Separa, Sofie Vandenbogaerde, Laura Vandewalle, Sadik Esener, Bradley T. Messmer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

High affinity and specificity are considered essential for affinity reagents and molecularly-targeted therapeutics, such as monoclonal antibodies. However, life's own molecular and cellular machinery consists of lower affinity, highly multivalent interactions that are metastable, but easily reversible or displaceable. With this inspiration, we have developed a DNA-based reagent platform that uses massive avidity to achieve stable, but reversible specific recognition of polyvalent targets. We have previously selected these DNA reagents, termed DeNAno, against various cells and now we demonstrate that DeNAno specific for protein targets can also be selected. DeNAno were selected against streptavidin-, rituximab-and bevacizumab-coated beads. Binding was stable for weeks and unaffected by the presence of soluble target proteins, yet readily competed by natural or synthetic ligands of the target proteins. Thus DeNAno particles are a novel biomolecular recognition agent whose orthogonal use of avidity over affinity results in uniquely stable yet reversible binding interactions.

Original languageEnglish (US)
Article numbere96
JournalNucleic Acids Research
Volume44
Issue number10
DOIs
StatePublished - Jun 2 2016
Externally publishedYes

Fingerprint

Nanoparticles
DNA
Proteins
Streptavidin
Monoclonal Antibodies
Ligands
Therapeutics
Bevacizumab
Rituximab

ASJC Scopus subject areas

  • Genetics

Cite this

Ruff, L. E., Sapre, A. A., Plaut, J. S., De Maere, E., Mortier, C., Nguyen, V., ... Messmer, B. T. (2016). Selection of DNA nanoparticles with preferential binding to aggregated protein target. Nucleic Acids Research, 44(10), [e96]. https://doi.org/10.1093/nar/gkw136

Selection of DNA nanoparticles with preferential binding to aggregated protein target. / Ruff, Laura E.; Sapre, Ajay A.; Plaut, Justin S.; De Maere, Elisabeth; Mortier, Charlotte; Nguyen, Valerie; Separa, Kevin; Vandenbogaerde, Sofie; Vandewalle, Laura; Esener, Sadik; Messmer, Bradley T.

In: Nucleic Acids Research, Vol. 44, No. 10, e96, 02.06.2016.

Research output: Contribution to journalArticle

Ruff, LE, Sapre, AA, Plaut, JS, De Maere, E, Mortier, C, Nguyen, V, Separa, K, Vandenbogaerde, S, Vandewalle, L, Esener, S & Messmer, BT 2016, 'Selection of DNA nanoparticles with preferential binding to aggregated protein target', Nucleic Acids Research, vol. 44, no. 10, e96. https://doi.org/10.1093/nar/gkw136
Ruff LE, Sapre AA, Plaut JS, De Maere E, Mortier C, Nguyen V et al. Selection of DNA nanoparticles with preferential binding to aggregated protein target. Nucleic Acids Research. 2016 Jun 2;44(10). e96. https://doi.org/10.1093/nar/gkw136
Ruff, Laura E. ; Sapre, Ajay A. ; Plaut, Justin S. ; De Maere, Elisabeth ; Mortier, Charlotte ; Nguyen, Valerie ; Separa, Kevin ; Vandenbogaerde, Sofie ; Vandewalle, Laura ; Esener, Sadik ; Messmer, Bradley T. / Selection of DNA nanoparticles with preferential binding to aggregated protein target. In: Nucleic Acids Research. 2016 ; Vol. 44, No. 10.
@article{7136947bb4094ee48b0e93be30d4e6f2,
title = "Selection of DNA nanoparticles with preferential binding to aggregated protein target",
abstract = "High affinity and specificity are considered essential for affinity reagents and molecularly-targeted therapeutics, such as monoclonal antibodies. However, life's own molecular and cellular machinery consists of lower affinity, highly multivalent interactions that are metastable, but easily reversible or displaceable. With this inspiration, we have developed a DNA-based reagent platform that uses massive avidity to achieve stable, but reversible specific recognition of polyvalent targets. We have previously selected these DNA reagents, termed DeNAno, against various cells and now we demonstrate that DeNAno specific for protein targets can also be selected. DeNAno were selected against streptavidin-, rituximab-and bevacizumab-coated beads. Binding was stable for weeks and unaffected by the presence of soluble target proteins, yet readily competed by natural or synthetic ligands of the target proteins. Thus DeNAno particles are a novel biomolecular recognition agent whose orthogonal use of avidity over affinity results in uniquely stable yet reversible binding interactions.",
author = "Ruff, {Laura E.} and Sapre, {Ajay A.} and Plaut, {Justin S.} and {De Maere}, Elisabeth and Charlotte Mortier and Valerie Nguyen and Kevin Separa and Sofie Vandenbogaerde and Laura Vandewalle and Sadik Esener and Messmer, {Bradley T.}",
year = "2016",
month = "6",
day = "2",
doi = "10.1093/nar/gkw136",
language = "English (US)",
volume = "44",
journal = "Nucleic Acids Research",
issn = "0305-1048",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Selection of DNA nanoparticles with preferential binding to aggregated protein target

AU - Ruff, Laura E.

AU - Sapre, Ajay A.

AU - Plaut, Justin S.

AU - De Maere, Elisabeth

AU - Mortier, Charlotte

AU - Nguyen, Valerie

AU - Separa, Kevin

AU - Vandenbogaerde, Sofie

AU - Vandewalle, Laura

AU - Esener, Sadik

AU - Messmer, Bradley T.

PY - 2016/6/2

Y1 - 2016/6/2

N2 - High affinity and specificity are considered essential for affinity reagents and molecularly-targeted therapeutics, such as monoclonal antibodies. However, life's own molecular and cellular machinery consists of lower affinity, highly multivalent interactions that are metastable, but easily reversible or displaceable. With this inspiration, we have developed a DNA-based reagent platform that uses massive avidity to achieve stable, but reversible specific recognition of polyvalent targets. We have previously selected these DNA reagents, termed DeNAno, against various cells and now we demonstrate that DeNAno specific for protein targets can also be selected. DeNAno were selected against streptavidin-, rituximab-and bevacizumab-coated beads. Binding was stable for weeks and unaffected by the presence of soluble target proteins, yet readily competed by natural or synthetic ligands of the target proteins. Thus DeNAno particles are a novel biomolecular recognition agent whose orthogonal use of avidity over affinity results in uniquely stable yet reversible binding interactions.

AB - High affinity and specificity are considered essential for affinity reagents and molecularly-targeted therapeutics, such as monoclonal antibodies. However, life's own molecular and cellular machinery consists of lower affinity, highly multivalent interactions that are metastable, but easily reversible or displaceable. With this inspiration, we have developed a DNA-based reagent platform that uses massive avidity to achieve stable, but reversible specific recognition of polyvalent targets. We have previously selected these DNA reagents, termed DeNAno, against various cells and now we demonstrate that DeNAno specific for protein targets can also be selected. DeNAno were selected against streptavidin-, rituximab-and bevacizumab-coated beads. Binding was stable for weeks and unaffected by the presence of soluble target proteins, yet readily competed by natural or synthetic ligands of the target proteins. Thus DeNAno particles are a novel biomolecular recognition agent whose orthogonal use of avidity over affinity results in uniquely stable yet reversible binding interactions.

UR - http://www.scopus.com/inward/record.url?scp=84973379945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973379945&partnerID=8YFLogxK

U2 - 10.1093/nar/gkw136

DO - 10.1093/nar/gkw136

M3 - Article

C2 - 26969734

AN - SCOPUS:84973379945

VL - 44

JO - Nucleic Acids Research

JF - Nucleic Acids Research

SN - 0305-1048

IS - 10

M1 - e96

ER -